Starting today, the Ozempic price in India will be cut by 36 percent, while Wegovy has seen a steeper 48 percent reduction — ...

The Drug Controller General of India (DCGI) has intensified regulatory oversight against the unauthorized sale and promotion ...

Top medical experts in India are sounding the alarm over the misuse of GLP-1 drugs like Ozempic for lifestyle weight loss, ...

Indian generic drugmakers launch a price war against Novo Nordisk’s GLP-1 brands, Ozempic and WeGovy.

The Government of India has tightened regulation of GLP-1 drugs used for diabetes and weight loss, restricting prescriptions ...

March 31 (Reuters) - Novo Nordisk on Tuesday cut the prices of its diabetes and weight-loss drugs Ozempic and Wegovy by as ...

A price war has hit India’s weight-loss and diabetes drug market after semaglutide lost patent protection, pushing innovator ...

India's drug regulator has intensified surveillance over GLP-1 weight loss drugs following the March patent expiry of ...

The GLP-1 drugs (glucagon-like peptide-1 receptor agonists) are developed to treat both type 2 diabetes and obesity by correcting hormonal imbalance - stimulating insulin release and suppressing ...

Novo Nordisk cuts prices of Wegovy and Ozempic in India by up to 48% amid rising competition from cheaper semaglutide ...

March 24 (Reuters) - India's drug regulator has tightened surveillance against the unauthorised sale and promotion of ...

Under EU law, active pharmaceutical ingredients (APIs) shipped from India and other non-listed countries must be supported by a written confirmation certificate stating the product meets good ...